• 1. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 2. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 3. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 4. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 5. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622

Research Briefing on 7-Methoxy-N-2-(7-methoxy-1-naphthalenyl)ethyl-1-naphthaleneethanamine (CAS: 1385018-57-4)

In recent years, the compound 7-Methoxy-N-2-(7-methoxy-1-naphthalenyl)ethyl-1-naphthaleneethanamine (CAS: 1385018-57-4) has garnered significant attention in the field of chemical biology and pharmaceutical research. This briefing aims to provide a comprehensive overview of the latest research developments related to this compound, focusing on its synthesis, biological activity, and potential therapeutic applications.

The compound, characterized by its unique naphthalene-based structure, has been investigated for its potential role in modulating various biological pathways. Recent studies have highlighted its affinity for specific neurotransmitter receptors, suggesting possible applications in neurological and psychiatric disorders. The synthesis of 7-Methoxy-N-2-(7-methoxy-1-naphthalenyl)ethyl-1-naphthaleneethanamine has been optimized to improve yield and purity, as reported in a 2023 study published in the Journal of Medicinal Chemistry.

One of the most promising findings involves the compound's interaction with serotonin receptors. In vitro and in vivo studies have demonstrated its selective binding to 5-HT2A and 5-HT2C receptors, which are implicated in mood regulation and cognitive function. These findings were corroborated by a recent preclinical trial, where the compound exhibited anxiolytic and antidepressant-like effects in animal models. The study, conducted by a team at the University of California, San Francisco, was published in Neuropharmacology earlier this year.

Additionally, research has explored the compound's potential in oncology. A 2022 study in Cancer Research revealed that 7-Methoxy-N-2-(7-methoxy-1-naphthalenyl)ethyl-1-naphthaleneethanamine could inhibit the proliferation of certain cancer cell lines, particularly those associated with breast and prostate cancers. The mechanism appears to involve the disruption of cell cycle progression and induction of apoptosis, though further studies are needed to elucidate the precise pathways involved.

Despite these promising results, challenges remain in the development of this compound for clinical use. Pharmacokinetic studies indicate that it has a relatively short half-life, necessitating the development of sustained-release formulations. Moreover, its solubility in aqueous solutions is limited, which could impact bioavailability. Researchers are currently exploring prodrug strategies and nanoparticle-based delivery systems to address these issues, as detailed in a recent review in Advanced Drug Delivery Reviews.

In conclusion, 7-Methoxy-N-2-(7-methoxy-1-naphthalenyl)ethyl-1-naphthaleneethanamine (CAS: 1385018-57-4) represents a promising candidate for further investigation in both neurological and oncological applications. Ongoing research is expected to provide deeper insights into its mechanisms of action and potential therapeutic benefits, paving the way for future clinical trials.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)